Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus CHOP in Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346Phase 2Terminated
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2004
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Waldenstrom macroglobulinemia (WM), sponsored by Eastern Cooperative Oncology Group. Started Oct 2004; status: terminated.
02
Drugs
rituximab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00060346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060346.